| Literature DB >> 26934957 |
Junji Kurashige1,2, Takanori Hasegawa3, Atsushi Niida4, Keishi Sugimachi1, Niantao Deng5, Kosuke Mima1,2, Ryutaro Uchi1, Genta Sawada1,6, Yusuke Takahashi1,6, Hidetoshi Eguchi1, Masashi Inomata7, Seigo Kitano7, Takeo Fukagawa8, Mitsuru Sasako9, Hiroki Sasaki10, Shin Sasaki11, Masaki Mori6, Kazuyoshi Yanagihara12, Hideo Baba2, Satoru Miyano4, Patrick Tan5, Koshi Mimori1.
Abstract
Peritoneal dissemination is the most frequent, incurable metastasis occurring in patients with advanced gastric cancer (GC). However, molecular mechanisms driving peritoneal dissemination still remain poorly understood. Here, we aimed to provide novel insights into the molecular mechanisms that drive the peritoneal dissemination of GC. We performed combined expression analysis with in vivo-selected metastatic cell lines and samples from 200 GC patients to identify driver genes of peritoneal dissemination. The driver-gene functions associated with GC dissemination were examined using a mouse xenograft model. We identified a peritoneal dissemination-associated expression signature, whose profile correlated with those of genes related to development, focal adhesion, and the extracellular matrix. Among the genes comprising the expression signature, we identified that discoidin-domain receptor 2 (DDR2) as a potential regulator of peritoneal dissemination. The DDR2 was upregulated by the loss of DNA methylation and that DDR2 knockdown reduced peritoneal metastasis in a xenograft model. Dasatinib, an inhibitor of the DDR2 signaling pathway, effectively suppressed peritoneal dissemination. DDR2 was identified as a driver gene for GC dissemination from the combined expression signature and can potentially serve as a novel therapeutic target for inhibiting GC peritoneal dissemination.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26934957 PMCID: PMC4776110 DOI: 10.1038/srep22371
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Establishment of the peritoneal dissemination signature in gastric cancer.
(a) EEM analysis was used to compare cell lines and clinical samples, which showed that a gene expression signature from the 58As9Luc cell line harbored a coherently expressed subset within the clinical gene set. Hierarchical clustering of primary tumor tissue from a cohort of 200 gastric cancer patients was performed using the top 200 gene sets (i.e. with highest expression) in 58As9 cells, compared with the parental HSC-58 cell line. Assuming that the 57 signature genes (right yellow box and genes list) in the coherent subset were clinically relevant, we extracted them as the gastric dissemination expression signature (GDES). The clinical characteristics of gastric cancer patients are shown at the top of the figure. Overall survival: patients that died following surgery are represented in the green box. Recurrence: patients showing recurrence are represented in the purple box. Grade: patients with a diffuse-type grade according to the Lauren classification are represented in the blue box. Peritoneal metastasis: patients with peritoneal tumors or who were cytology-positive at the time of surgery are represented in the red box. Data deficiencies are represented in the gray box. (b) The high module activity of the GDES significantly associated with peritoneal metastasis. (c) Patients with high GDES module activity showed significantly poorer overall survival rates, compared to those with low GDES activity.
Figure 2DDR2 expression was associated with peritoneal dissemination and poor prognosis in gastric cancer.
(a) EEM-deduced activity profiles of GDES and other gene sets were evaluated by clustering analysis. (b) Kaplan–Meier survival curves for the 198 patients in the Singaporean cohort, with classification based on DDR2 mRNA expression levels measured using a microarray. (c) DDR2 expression was significantly higher in gastric cancer patients with peritoneal metastasis (Singaporean cohort). (d) Kaplan–Meier survival curves for the 195 patients in the Japanese cohort, as measured by qRT-PCR. (e) High DDR2 expression associated with gastric cancer patients that developed peritoneal metastasis, as determined by performing a Pearson’s chi-square test (Japanese cohort).
Figure 3DDR2 overexpression was associated with DNA demethylation and epithelial-mesenchymal transition in gastric cancer.
(a) Correlation plot between DDR2 expression and the fraction of methylation at the promoter region of DDR2 in 173 gastric cancer samples from the Singaporean cohort. (b) Box plot of the fraction of DDR2 promoter methylation between patients, with or without peritoneal metastasis. (c) Representative images of DDR2 and E-cadherin protein expression in gastric cancer cells. Scale bars, 100 μm. (d) DDR2 and E-cadherin expression were inversely correlated by immunohistochemical analysis of 76 gastric cancer samples.
Figure 4DDR2 inhibition reduced gastric cancer peritoneal metastasis in vitro and in vivo.
(a) DDR2 expression was suppressed in 58As9Luc cells by 2 independent shRNAs. (b) DDR2 knockdown resulted in lower cell proliferation on collagen I-coated 96-well plates, but did not affect cell proliferation on normal plates. (c,d) Effects of DDR2 on (c) cancer cell migration and (d) invasion. (e) DDR2-knockdown 58As9Luc cells were orthotopically transplanted into the stomach walls of nude mice. (f,g) The normalized weight of gastric wall tumors (f) and the number of disseminated metastatic tumors (g) at 28 days post-transplantation with 58As9Luc cells with silenced DDR2 expression. Control, DDR2 sh#1, and sh#2: n = 8. *p < 0.05, **p < 0.01.
Figure 5Dasatinib inhibited peritoneal dissemination.
(a) Mice were treated orally and intraperitoneally with dasatinib at 50 mg/(kg·day) or a vehicle control, beginning at day 14 post-transplantation with 58As9Luc cells into the gastric wall. At day 28 post-transplantation, the mice were visualized using the IVIS system. (b) Macroscopic images showed an enlarged peritoneal cavity and metastatic nodules by controlMock3 and shDDR2. Arrowheads show nodules. (c) Normalized bioluminescence photon flux of disseminated peritoneal tumors at day 28 post-transplantation, as visualized by the IVIS system. The control and orally plus intraperitoneally administered dasatinib groups each contained n = 8 mice. **p < 0.01. (d) Survival curves showed that survival rate in dasatinib-treated mice was significantly higher (*p < 0.05) than that in control mice. (e) Src and Src phosphorylation, as measured by immunoblotting.